---
id: 018
title: Aminoglycoside PK/PD and Once-Daily Dosing
category: antimicrobials
subcategory: pharmacokinetics_pharmacodynamics
tags: [aminoglycoside, Cmax/MIC, AUC/MIC, once-daily, concentration-dependent]
difficulty: medium
---

## Question

What PK/PD parameters predict aminoglycoside efficacy, and why is **once-daily dosing** preferred over divided dosing?

## Answer

### **PK/PD Targets:**

| Parameter | Target Value | Clinical Outcome |
|-----------|-------------|------------------|
| **Cmax/MIC** | **>10** (ideally 10-12) | Predicts bacterial eradication |
| **AUC₂₄/MIC** | **>100-125** | Predicts clinical success (Gram-neg) |

### **Rationale for Once-Daily Dosing:**

1. **Concentration-dependent killing:**
   - Higher peak → faster/greater bacterial kill
   - Linear relationship between Cmax and bacterial eradication rate

2. **Prolonged post-antibiotic effect (PAE):**
   - PAE duration: 2-8 hours for Gram-negatives
   - Bacterial suppression persists after drug levels drop <MIC

3. **Reduced toxicity:**
   - Nephrotoxicity correlates with **trough levels** (time >2 mg/L)
   - Once-daily dosing → longer drug-free interval → less proximal tubule uptake
   - Comparable or better safety vs divided dosing

### **Dosing Example:**
- **Gentamicin/tobramycin:** 5-7 mg/kg IV q24h
- **Target peak:** 20-30 mg/L (draw 30-60 min post-infusion)
- **Target trough:** <1 mg/L (draw just before next dose)

## Key Points

- Avoid aminoglycosides in **acidic/hypoxic environments** (abscess, empyema) - poor penetration
- Dose by **actual body weight** (not ideal/adjusted)
- Extended-interval dosing NOT validated for endocarditis (use divided dosing q8-12h for synergy)

## Sources

- [PMC3675903: PK and PD of Antibacterial Agents]
- [IBCC: Aminoglycoside dosing and monitoring]
- [PMC5039113: PK/PD Principles]

## Media

N/A
